SynB3-PVGLIG-PTX

SynB3-PVGLIG-PTX is an experimental **peptide-drug conjugate** designed to overcome blood-brain barrier penetration challenges in glioblastoma treatment. The drug consists of paclitaxel conjugated to a dual-functional peptide system: **SynB3** (a cell-penetrating peptide) and **PVGLIG** (a matrix metalloproteinase-2 sensitive peptide). The mechanism involves the SynB3 peptide facilitating BBB penetration, while the MMP-2-sensitive PVGLIG linker enables targeted drug release specifically at glioblastoma tumor sites where MMP-2 is overexpressed[1][2]. The conjugate forms water-soluble, positively charged nanoaggregates that demonstrate superior brain penetration and tumor-specific accumulation compared to free paclitaxel[2].